GoKawiilQuest Diagnostics to offer at-home BD Onclarity HPV test nationwide in 2025
Quest Diagnostics will roll out an at-home HPV self-collection test using BD's Onclarity assay to patients across the U.S. starting next year. The FDA cleared the test for home use in April, allowing women to collect a sample themselves instead of undergoing an in-clinic pelvic exam.
GoKawiil's interpretation of the reporting above, not reported fact.
Removing the need for a speculum exam could lower a major barrier that keeps some women from getting regular cervical cancer screening, potentially catching more HPV infections earlier. Wider adoption through a major lab network like Quest suggests at-home collection could become a mainstream option rather than a niche offering, though actual uptake and insurance coverage will determine how much impact it has.
- BD's Onclarity HPV assay received FDA clearance for home use in April
- Quest Diagnostics plans national rollout of the at-home test starting in 2025
- The test eliminates the need for an in-person pelvic exam for sample collection
Source: fastcompany.com, 2026-10-20
Published there as: “A new at-home HPV test kit is going national through Quest Diagnostics”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.